Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Glioblastoma 12Prostatic Neoplasms 11Oropharyngeal Neoplasms 10Lung Neoplasms 10Carcinoma, Non-Small-Cell Lung 10Breast Neoplasms 9Glioma 8Urinary Bladder Neoplasms 7Squamous Cell Carcinoma of Head and Neck 6Esophageal Neoplasms 6Neoplasm Metastasis 5Mouth Neoplasms 5Carcinoma 5Burkitt Lymphoma 5Astrocytoma 5Sarcoma 4Pancreatic Neoplasms 4Laryngeal Neoplasms 4Gliosarcoma 4Carcinoma, Hepatocellular 4Brain Neoplasms 4Adenocarcinoma of Lung 4Adenocarcinoma Of Esophagus 4Uterine Cervical Neoplasms 3Triple Negative Breast Neoplasms 3Stomach Neoplasms 3Rhabdomyosarcoma, Embryonal 3Rhabdomyosarcoma 3Rectal Neoplasms 3Neoplasms 3

Interventions

atezolizumab 3Specimen Handling 2Magnetic Resonance Spectroscopy 2talazoparib 1Radiotherapy 1Radiation 1LB100 1Etoposide 1Carboplatin 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Extensive Stage Lung Small Cell Carcinoma × Radiation × 90 days × Clear all
NCT04402788 2026-06-02

Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial

National Cancer Institute (NCI)

Phase 2/3 Recruiting
138 enrolled

Extensive Stage Lung Small Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡